proteins
Recombinant antigens
Recombinant allergens
Custom-made
HRP-conjugated
Monobiotinylated
Multi-epitope
antibodies
Polyclonals
Custom-made
Blockers
Pipeline
About
Rekom Biotech
About us
Quality
Images gallery
Upcoming events
Collaborators
Financing
Electronic site
IVD Reagents
General features
Scientific & technical information
Promotional material
Others
Infectious diseases
Allergies
Expression systems
Blog
Contact
Contact information
Distributors
Español
Blog
REKOM BIOTECH in Almuñécar Digital
REKOM BIOTECH in Almuñécar Digital
11/2/2017
Rekom Biotech appeared on
November 2017, 2th
in Almuñécar digital newspaper.
CATEGORY:
PRESS
TOPICS OF INTEREST
COVID-19 (SARSCOV-2)
EVENTS
NEWS
PRESS
SCIENTIFIC NOTES
TRADEFAIRS AND CONGRESSES
HIGHLIGHTS
The IDEA Agency grants Rekom Biotech an incentive to develop new recombinant antigens for the detection of Dengue
REKOM BIOTECH implements the ISO 13485 standard
Rekom Biotech is listed as one of the top ten leading vendors in the Insight Partners' Viral Antigens Market Forecast to 2027 report
Vaccination vs Natural infection. A diagnostic challenge in COVID-19 asymptomatic patients, when the immunity profile is not known.
Why choose a recombinant antigen?